‘Les liaisons dangereuses’: Hepatitis C, Rituximab and B-cell non-Hodgkin’s lymphomas

Rituximab has provided a revolutionary contribution to the treatment of B-cell non-Hodgkin’s lymphomas (NHL). A high prevalence of hepatitis C virus (HCV) infection has been described in B-cell NHL patients. Cases of liver dysfunction in HCV-positive patients have been reported with Rituximab-containing regimens. In this paper we review the recent data regarding the effects of Rituximab in NHL patients with HCV infection. We also added a section devoted to improving communication between oncohaematologists and hepatologists. Furthermore, we propose a common methodological ground to study hepatic toxicity emerging during chemotherapy.

Ultrasound features of primary non-Hodgkin’s lymphoma of the palatine tonsil:A case report

BACKGROUND Lymphomas are the second most common malignancy of the head and neck.In this region,the vast majority of extranodal lymphomas are located in the palatine tonsil,accounting for about 51%.Tonsillar lymphomas are aggressive tumors with intermediate-or high-grade histology.We here report a case of primary non-Hodgkin’s lymphoma of the palatine tonsil and analyze its ultrasound features.CASE SUMMARY A 40-year-old man presented with right palatine tonsil swelling for 2 mo after a cold,accompanied by dysphagia,snoring,and suffocation.He had no sore throat,fever,or history of upper respiratory tract infection or tuberculosis.The patient was generally in good health and denied other diseases.He was diagnosed with acute tonsillitis initially and treated with antibiotics for 7 d.However,there was no improvement with the treatment.Tonsil biopsy and ultrasound-guided biopsy of the biggest lymph node of the right neck showed the typical pathology of non-Hodgkin lymphoma.CONCLUSION Primary lymphoma of the tonsils is rare,and its diagnosis is challenging.Ul-trasound is a useful modality in diagnosing oropharyngeal diseases,and can clearly show the features of this tumor,but the final diagnosis should be estab-lished by histology.

Post-Therapy Profile of BMI-for-Age of Indian Survivors of Pediatric Acute Lymphoblastic Leukemia and Non-Hodgkin’s Lymphoma

Background: Obesity in pediatric ALL survivors is a well recognized late effect. Hence the present study examines the BMI-for-age of Indian childhood ALL and NHL survivors. Method: A retrospective study of 118 ALL/NHL survivors and 138 age sex matched was carried out. From the recorded heights and weights were body mass index (BMI) was computed. The survivor data was compared with 138 controls from the data set collected by investigators previously. Results: 82.8% of patients had BMI-for-age in 5th-84th percentile (healthy) at time of diagnosis and at inclusion in the study. Comparison of BMI of survivors with matched controls was not significant. However, The mean BMI-for-age for younger patients (3 to 12 years) was significantly higher than mean BMI-for-age of matched controls. Distribution of data by time elapsed from therapy was significant. Overweight/obesity was observed among the survivors who were off therapy for two years with increase in after four years post-therapy. Conclusion: Our preliminary study indicates late effects of therapy and points to the need of long term assessment of the survivors, even though majority of them were within the normal weight range.

Cost-Minimization and Budget Impact Analysis of Rituximab SC VS Rituximab IV for Non-Hodgkin’s Lymphoma (NHLs) in Greece

Background: Non-Hodgkin’s lymphoma (NHLs) is a prevalent type of cancer for which Intravenous (IV) Rituximab is a widely used treatment option. Nevertheless, IV infusions can lead to intense resource use and, subsequently, costs. Given that a subcutaneous (SC) therapeutically equivalent formulation of the drug is currently available, this study aimed to examine the potential clinical and economic value of the introduction of the SC formulation for the Greek healthcare setting. Methods: A cost-minimization and budget-impact analysis contributed to comparing staff, patient time and resource utilization and estimating the clinical effects and associated costs in the IV and SC administration. A questionnaire-based survey was used to provide data regarding the local treatment patterns and the resource use associated with each treatment in the Greek NHS. The analysis followed the third-party payer perspective, and cost data relevant to personnel salaries, pharmaceuticals and resource utilization were obtained from official government sources. Results: SC administration was associated with time savings in activities such as pre-medication administration (3 minutes saved with the SC use), monitoring during infusion (12 minutes for physicians and 3 minutes for nurses) as well as time-savings in the preparation of the drugs, the actual dispensing process and the post-injecting monitoring processes. A significant decrease was observed in the nursing and chair time (57% and 90% per case, respectively) and a higher level of services could be secured in terms of hospital capacity with the SC use. SC administration was found to generate budget savings of 618,708€ per 1000 patients/3 years over the full course of treatment. Conclusions: Switching IV to SC administration, as demonstrated in the case of Rituximab for NHLs in Greece, can reduce staff time and administration costs, improve the capacity of the system and, possibly, improve resource allocation in the healthcare system.

Unusual Case of Idiopathic Membranous Later Developing Non-Hodgkin’s Lymphoma

A 30-year-old male presented to nephrology services as a case of nephrotic syndrome and membranous nephropathy was found on renal biopsy. He was treated for this pathology with steroid and cytotoxic drugs and remained in remission for 3 years and then presented with non Hodgkin’s lymphoma.

Unusual Presentation of Non-Hodgkin’s B-Cell Lymphoma with Unilateral Right Limb Lymphedema

Background: In clinical practice and setting of general practice it is common to see patients with leg edema. To correctly identify the etiology of the edema and then properly manage the cause is not always easy. The unilateral lymphedema of the lower limb has rarely been reported as an initial presentation for lymphoma, especially in females, usually without classic signs or symptoms, but often with inguinal lymphadenopathy or abdominal masses. Case Report: In this article, we report a rare case of unilateral lower limb edema in a healthy obese woman who complained about the appearance of the disease for several months and for whom deep vein thrombosis and other diseases had been excluded. The histological examination of the biopsy of an enlarged lymph node in the right groin, which was compressing the iliac and femoral vein, revealed the presence of B cell non-Hodgkin lymphoma with high-grade malignancy. Conclusions: A common challenge for primary care physicians is to determine the cause and find an effective treatment for leg edema of unclear etiology. Non-Hodgkin’s B-cell Lymphoma should be considered in the differential diagnosis in patients with unilateral leg edema when the swelling is chronic and deep venous thrombosis is promptly excluded.

Primary Ovarian Non-Hodgkin’s Lymphoma: Retrospective Study of 16 Patients

Background: Primary non-Hodgkin’s lymphoma (PONHL) of the ovary is rare disease. Ovarian involvement by NHL is usually secondary, as a part of systemic disease. It is frequently diagnosed as ovarian carcinoma which causes a significant delay in diagnosis and management. Objective: To analyze, to report and to better understand the clinico-pathologic features and results of treatment, and prognostic factors of these tumors. Material & methods: This was a retrospective single institutional work that included 16 cases of primary ovarian non-Hodgkin lymphoma (PONHL) treated in National Cancer Institute-Cairo University from January 2010 till January 2015. All available medical data including the clinical and pathological characteristics, treatment, and outcomes of patients with PONHL are analyzed. Results: Data from 16 patients are obtained. The patient’s age ranges from 14 to 55 years (mean 28 years). Ascites is the most common manifestation (75%). Tumor size ranges from 5 to 24 cm (mean 13.1). LDH is elevated in all cases (mean 644 U/L) and CA-125 is elevated in only 4 cases (25%) especially when there is an extensive peritoneal irritation. Ten cases (62.5%) are bilateral with stage IV-E according to the Ann Arbor staging system. The remaining six cases (37.5%) are unilateral with Ann Arbor stage I-E. There are no stage II-E or III-E in the current study. Tumors are classified according to the World Health Organization as follows: diffuse large B-cell lymphoma (10 cases) (62.5%), Burkitt’s lymphoma (5 cases) (31%) and only one case of B-lymphoblastic lymphoma/leukemia. All the tumors are of B-cell lineage and are all CD20 positive. All Burkitt’s lymphoma cases show higher Ki67 index (4 cases are 100% and one is 88%). The case of B-lymphoblastic lymphoma/leukemia is positive for TDT & CD 10. Surgery is the main treatment modality for primary diagnosis and for staging, although chemotherapy should have been the primary treatment because it is one of the most chemosensitive tumors. Follow-up period ranges from 3 months to 5 years (mean 33 months). Ten patients are alive without disease. Two cases experienced relapse and one case died during chemotherapy treatment. The remaining three cases died from other causes than disease. The median overall survival time was not reached yet;however, the mean overall survival was 46.8 monthes;median progression free survival was 36 months. Conclusion: Most patients with PONHL present with symptoms attributable to an ovarian mass which necessitates extensive surgical staging that is not mandatory for lymphomas. More studies will be needed to better define and treat this rare entity.

Clinical Outcomes of 67 Patients Treated with Chemoradiotherapy for Primary Thyroid Non-Hodgkin’s Lymphoma in Osaka Medical College

Background: The reports of clinical outcomes of patients treated with chemoradiotherapy for primary thyroid non-Hodgkin’s lymphoma are rare. We report our results of chemoradiotherapy for primary thyroid non-Hodgkin’s lymphoma. Materials and Methods: The subjects were 67 patients with thyroid non-Hodgkin’s lymphoma among 269 patients with malignant lymphoma who received radiotherapy in our hospital during a period between May 1990 and June 2005. The patients included 16 men and 51 women, with a mean age of 66.2 ± 10.7 years (30 - 84 years). The disease stage was stage I in 42 patients, stage II in 24, and unclear in 1. The histologic type was B-cell lymphoma in 66 patients, MALT in 9, diffuse type in 52, follicular type in 5, and diffuse and follicular type in 1. CHOP chemotherapy regimen for malignant lymphoma patients was as follows. Intravenous drip infusion of cyclophosphamide 750 mg/m2, (drip) infusion of doxorubicin 50 mg/m2, and intravenous injection of vincristine 1.4 mg/m2 were administered on day 1, followed by 5 consecutive days of oral prednisolone 100 mg/m2. This regimen was repeated every 3 weeks (21 days) in 6 to 8 courses. Modified CHOP chemotherapy regimen was as follows. Intravenous drip infusion of cyclophosphamide 600 mg/m2, intravenous (drip) infusion of doxorubicin 40 mg/m2, intravenous infusion of vindesine 3 mg/m2, and intravenous drip infusion of prednisolone 60 mg/body were administered on day 1, and intravenous prednisolone was changed to oral prednisolone with the dose tapered gradually. After completing one course of this regimen, two courses of radiotherapy (a total of 36 Gy) were performed, followed by 6 courses of the chemotherapy regimen at lower doses (80% of the initial doses) repeated once a month. Results: Results of chemoradiotherapy in all patients were excellent. The 15-year survival rate was over 80%. Although there were no significant differences in the results of chemoradiotherapy among different histologic types of thyroid malignant lymphoma, the survival rate was 100% for MALT type, as compared with poor results for diffuse large type or diffuse mixed type. The analysis of the results of chemoradiotherapy according to the stage of malignant thyroid lymphomas revealed that therapeutic results were significantly better in stage I than in stage II. Conclusion: The CHOP chemoradiotherapy regimen and modified CHOP chemoradiotherapy regimen were excellent for primary thyroid non-Hodgkin’s lymphoma.

LMP1 Immunohistochemistry in Non-Hodgkin’s Lymphoma of Sudanese Cases

Back ground: Non-Hodgkin’s lymphoma (NHL) with its different subtypes is strongly related to Epstein Bar virus (EBV) infection mainly Burkitt’s lymphoma in Africa. Studies proved the role of EBV in tumor-genesis and linked it to prognosis and therapy of patients. Objectives: To determine the frequency of EBV in non-Hodgkin lymphomas using EBV latent membrane protein 1 (EBV-LMP1) immunohistochemical stain. Methods: This cross-sectional study was conducted at radio-isotope centre of Khartoum (2012-2014). A total of 75 cases of non-Hodgkin lymphoma paraffin embedded sections were stained for EBV LMP1 antibody. Data were analyzed by SPSS 16 and statistical cross linking of the results of immune staining with other data was done. Results: Out of 75 patients of non Hodgkin’s lymphoma (74.7%) were males. EBV-LMP1 Immune-staining was positive in (17.3%) with predominance of Burkitt’s lymphoma (33.3%), followed by diffuse large B cell lymphoma (17.9%). Conclusion: Burkitt’s lymphoma expressed the highest percentage of non-Hodgkin’s lymphoma positive cases (46.2%) out of the total (17.3%) positive cases. Different methods need to be used in studying Burkitt’s lymphoma expression of EBV and its effects on the treatment and prognosis of cases.

Low Dose Total Body Irradiation for Relapsed Low Grade Non-Hodgkin’s Lymphoma: Experience of National Cancer Institute, Cairo

Background and Purpose: The relapsed low grade non-Hodgkin’s lymphoma (LG-NHL) is currently?incurable disease and the optimal treatment regimen has not determined yet. Low dose total body irradiation (LTBI) provides an alternative mechanism of action against cancer cells rather than direct cell kill. The mode of action of LTBI is immune-modulatory effect, induction of apoptosis and?hypersensitivity to low radiation doses. The aim of our study is to evaluate the effect of LTBI on relapsed?LG-NHL and reporting our experience at National Cancer Institute, Cairo (NCI, Cairo). Material and Methods: Fifty eight patients with relapsed LG-NHL and received LTBI studied retrospectively.?LTBI dose was 1.6 Gy/8 fractions divided on 2 courses;each course 4 fractions treated over 4 days with 2 weeks rest between the 2 courses. Results: The median age is 54 years;65% of the patients are men. Forty (69%) patients had performance status of 2 or more. Twenty seven patients were stage II/III and 31 patients (53%) had stage IV disease. Twenty six (45%) patients had bulky disease more than 10 cm and 22 (38%) patients had B symptoms at the time of relapse. The?extranodal disease was present in 17 patients (29%) and 78% of the patients received?>3 regimens of chemotherapy before referral to LTBI. Twenty three patients received IFRT (mean dose 32 ± 4 Gy) to initially bulky sites after LTBI. Fourteen patients (24%) achieved complete remission (CR) while 45%, 21% and 10% had partial remission (PR), stable disease (SD) and progressive disease (PD) respectively. The median PFS duration was 14 months and the median OS duration?was 39 months. Stage VI,?>3 regimen of chemotherapy and bad response to LTBI (SD) affected?progression duration adversely (0.03, 0.05 and 0.01 respectively). The response to LTBI is the only factor affected the OS duration significantly. The 3-year PFS was 19% ± 9%, and 3-year OS was 45% ± 8%. Stage IV was the only factor affected the 3-year PFS significantly with p value 0.03. The hematological toxicity was the main side effect of LTBI. Eleven patients developed G3/4 anemia while 8 patients only developed G3/4 thrombocytopenia and 13 patients developed G3/4 leucopenia. Conclusion: The use of LTBI in patients with relapsed low grade NHL is a feasible, effective and tolerable treatment that is worthy of testing in a future with chemotherapy and Rituximab maintenance.

SENEX-mediated CDK4/6 inhibition promotes senescence and confers apoptosis resistance in B-cell non-Hodgkin lymphoma

Background:The primary cause of treatment failure in patients with refractory or relapsed B-cell non-Hodgkin lymphoma(r/r B-NHL)is resistance to current therapies,and therapy-induced senescence(TIS)stands out as a crucial mechanism contributing to tumor drug resistance.Here,we analyzed SENEX/Rho GTPase Activating Protein 18(ARHGAP18)expression and prognostic significance in doxorubicin-induced B-NHL-TIS model and r/r B-NHL patients,investigating its target in B-NHL cell senescence and the effect of combining specific inhibitors on apoptosis resistance in B-NHL-TIS cells.Methods:Raji cells were transfected with the human SENEX shRNA recombinant lentiviral vector(Sh-SENEX)and the empty vector negative(NC)to construct a stable transfection cell line with knockdown of SENEX.Effect of SENEX-silencing on B-NHL-TIS formation,cell function and cell cycle-related pathways was analyzed.Using doxorubicin(DOX)-inducible senescent B-NHL cells combined with the specific cyclin dependent kinase 4/6(CDK4/6)inhibitor Palbociclib to observe that blocking CDK4/6 effects on TIS formation.SENEX expression of 21 B-NHL patients and 8 healthy controls were analyzed by qRT-PCR,and the correlation between its expression and clinical indicators were evaluated.Results:The downregulation of SENEX expression promotes G1-S phase transition and apoptosis while inhibiting cell proliferation,collectively suppressing the formation of TIS in B-NHL.Blockade of CDK4/6 promotes the DOX-induced G1 phase arrest to enhance TIS formation in B-NHL cells which can reverse the regulatory effect of silencing SENEX on B-NHL cell cycle regulation and senescence.The expression levels of SENEX were notably elevated in B-NHL patients compared to healthy controls,and Elevated expression levels of SENEX were associated with poor prognosis of B-NHL patients.Conclusions:SENEX enhances apoptosis resistance in B-NHL by inhibiting CDK4/6,thereby preventing G1-S phase transition and promoting TIS formation.

妊娠糖尿病患者蛋白C、蛋白S和抗凝血酶Ⅲ水平及其与孕周的关系

目的探讨妊娠糖尿病(GDM)患者蛋白C(PC)、蛋白S(PS)和抗凝血酶Ⅲ(ATⅢ)水平及其与孕周的关系。方法选择2019年1月至2023年3月在医院就诊的232例GDM孕妇作为观察组,同时随机选取同期在医院进行孕检的268例正常孕妇作为对照组,比较两组一般资料和PC、PS和ATⅢ水平;按孕周将观察组和对照组分为孕中期和孕晚期,分别比较孕中期和孕晚期观察组和对照组PC、PS和ATⅢ水平。通过相关性分析,分析PC、PS和ATⅢ水平与孕周的相关性。结果与对照组相比,观察组PS和PC水平降低(P<0.05),但ATⅢ水平差异无统计学意义(P>0.05)。GDM患者PC和ATⅢ水平与孕周呈负相关(r=-0.156、-0.134,P<0.05)。结论GDM患者PS和PC水平降低,且随孕周增大,PC、PS和ATⅢ水平降低,应尽早进行干预,以减少血栓形成的风险。

结合主动光源和改进YOLOv5s模型的夜间柑橘检测方法

【目的】解决夜间环境下遮挡和较小柑橘难以准确识别的问题,实现采摘机器人全天候智能化作业。【方法】提出一种结合主动光源的夜间柑橘识别方法。首先,通过分析主动光源下颜色特征不同的夜间柑橘图像,选择最佳的光源色并进行图像采集。然后,提出一种夜间柑橘检测模型BI-YOLOv5s,该模型采用双向特征金字塔网络(Bi-FPN)进行多尺度交叉连接和加权特征融合,提高对遮挡和较小果实的识别能力;引入Coordinate attention(CA)注意力机制模块,进一步加强对目标位置信息的提取;采用融入Transformer结构的C3TR模块,在减少计算量的同时更好地提取全局信息。【结果】本文提出的BI-YOLOv5s模型在测试集上的精准率、召回率、平均准确率分别为93.4%、92.2%和97.1%,相比YOLOv5s模型分别提升了3.2、1.5和2.3个百分点。在所采用的光源色环境下,模型对夜间柑橘识别的正确率为95.3%,相比白光环境下提高了10.4个百分点。【结论】本文提出的方法对夜间环境下遮挡和小目标柑橘的识别具有较高的准确性,可为夜间果蔬智能化采摘的视觉精准识别提供技术支持。

HBsAg和HBsAb共存的慢性乙肝患者的血清学特征和S区突变位点

目的探讨HBsAg/HBsAb双阳患者和HBsAg单阳性患者的血清学差异,并对两组患者的HBV S区突变位点进行比较分析,探寻HBsAg/HBsAb共阳性患者可能的分子机制。方法选取首都医科大学附属北京佑安医院2022年6月至2023年3月的284例HBsAg/HBsAb双阳患者和519例HBsAg单阳患者,统计Age、ALT、AST、AST/ALT、TBiL、ALb、r-GT、HBsAg和HBsAg滴度、HBsAb、HBeAg、HBeAb、HBcAb、WBC,对两组患者的血清学指标进行比较分析。对HBV S区扩增成功的19例HBsAg/HBsAb双阳患者和19例HBsAg单阳患者进行测序分析,统计高频突变位点,分析HBV S区突变特征,探寻HBsAg/HBsAb双阳患者可能发生的分子机制。结果HBsAg/HBsAb双阳患者和HBsAg单阳患者在性别、HBeAg、ALT、AST、TBiL、r-GT差异有统计学意义(P<0.05)。两组患者在Age、HBeAb、HBcAb、AST/ALT、Alb、WBC差异无统计学意义(P>0.05)。HBsAg/HBsAb双阳组患者C基因型占78.95%(15/19),其中A113D/T、A317C/S、A45T、A86G、A87T、A96V、A97P等突变频率较高,HBsAg单阳组C基因型占84.21%(16/19),V159A、M47T、I213L、A317S、E44G、Q267L突变频率较高,两组患者的高频突变位点明显不同。结论双阳和单阳CHB患者血清学和基因突变位点存在显著差异。建议针对HBV S区不同的突变位点进一步研究HBsAg和HBsAb共存的机制。

三维各向异性TI介质中的P/S波快速解耦技术及在弹性波逆时偏移中的应用

随着多分量采集技术的发展,弹性波逆时偏移技术在三维各向异性介质复杂地质构造成像中得到了广泛的应用.然而耦合的P波场和S波场,会在传播过程中产生串扰噪声,降低弹性波逆时偏移的成像精度.为了解决这一问题,本研究针对具有倾斜各向异性对称轴的三维横向各向同性(Transverse Isotropy,TI)介质,提出了一种矢量弹性波场快速解耦方法,可以有效提高偏移剖面的成像质量.该方法首先通过坐标转换,将观测系统坐标系的垂直轴旋转到TI介质的对称轴方向,在新坐标系下,根据具有垂直对称轴的三维横向各向同性(Vertical Transverse Isotropy,VTI)介质中的分解算子,推导出三维TI介质解耦算子表达式.接着引入一种在空间域快速计算分解波场的方法,来实现空间域矢量P波场和S波场分离,极大地提高了计算效率.最后,通过点积成像条件,将提出的P/S波分解方法引入到三维TI介质弹性波逆时偏移中,得到高精度的PP和PS成像.与以往的波场分解方法相比,本文方法具有数值稳定和计算效率高的特点.数值算例表明,应用上述三维TI分解算子得到的偏移剖面有效压制了噪声,提高了成像质量.

基于多目标遗传算法的8×8 S盒的优化设计方法

混沌系统具有非线性、伪随机性、初始值敏感等特性,为基于动力系统构造性能良好的S盒提供了基础,进一步保证了分组加密算法安全性.目前,基于混沌构造S盒的方法大多数针对单个性能指标进行优化,难以获得全面的性能提升.针对此问题,结合混沌映射与多目标遗传算法,提出了一种新的S盒设计方法.首先,利用混沌映射的特性产生初始S盒种群;然后,以S盒的非线性度和差分均匀性为优化目标,基于遗传算法框架对上述两指标进行优化.针对S盒的特点,在优化算法中引入了交换操作,设计了新的变异操作以及非支配序集计算,有效提升了S盒的非线性度和差分均匀性.实验结果表明该算法产生的S盒其差分均匀度为6,非线性度值至少为110,有效提升了S盒的综合性能.

基于S变换双阈值法的汽车零部件载荷谱加速编辑

针对S变换编辑法加速编辑效果不佳的问题,提出了一种基于S变换双阈值编辑方法。该方法先对载荷谱进行S变换以获取最大幅值谱,在以双阈值识别并保留的幅值谱片段为依据保留对应的载荷谱片段后,再将其拼接成加速后的载荷谱,最后对比分析S变换双阈值编辑法与S变换编辑法编辑的加速谱的统计参数、功率谱密度、穿级计数和疲劳仿真结果。研究结果表明,S变换双阈值编辑法可明显压缩原始载荷时间,且其压缩效率高于S变换编辑法,转向节的疲劳损伤和寿命分析误差更小,适用于汽车零部件载荷谱加速编辑研究。

改变导叶翼型对水泵水轮机“S”特性的影响

针对水泵水轮机“S”特性区域的不稳定性问题,提出使用改型活动导叶翼型进行性能提升.以某水泵水轮机模型为研究对象,采用SST k-ω湍流模型对水泵水轮机全流道进行三维数值计算,通过对活动导叶翼型的改型设计,得出流量-转速模拟曲线,分析水泵水轮机组“S”特性改善情况.将计算与试验结果进行对比,并对改型活动导叶翼型前后机组的无叶区进行压力脉动分析.结果表明:在保证整体效率依然保持在92%附近的前提下,新的活动导叶翼型对机组的“S”特性依旧具有改善效果;无叶区压力脉动主要是受到活动导叶叶栅区域的分流在此重新聚集影响,并且与转轮叶片的动静相互扰动引起的;改型后的活动导叶降低了无叶区的压力脉动幅值,提升了水泵水轮机运行中的并网稳定性.

S型异质结光催化剂ZnFe_(2)O_(4)/WO_(3)的构筑及光催化还原CO_(2)性能

通过在WO_(3)纳米片表面负载ZnFe_(2)O_(4)纳米颗粒,构建了一系列S型异质结光催化剂ZnFe_(2)O_(4)/WO_(3),并研究了其光催化CO_(2)还原性能。在没有助催化剂和牺牲剂的条件下,所制备的ZnFe_(2)O_(4)/WO_(3)复合材料可对CO_(2)与水蒸汽进行光催化反应。优化后的材料光照5 h后CO_(2)还原产物CO和CH_(4)的产量分别为7.87和4.88μmol·g^(-1)。相对于单相组分,CO和CH_(4)的产量明显提高。光催化活性的提高,归因于ZnFe_(2)O_(4)和WO_(3)异质结的形成以及光生载流子的S型电荷传输模式。

基于量子衍生涡流算法和T⁃S模糊推理模型的储层岩性识别

鉴于梯度下降法易陷入局部极值、普通群智能优化算法易早熟收敛,提出一种基于量子衍生涡流算法(Quantum Vortex Search Algorithm,QVSA)和T⁃S模糊推理模型的岩性识别方法,QVSA具有操作简单、收敛速度快、寻优能力强等优点,有助于T⁃S模糊推理模型获得最优参数配置,从而实现储层岩性的准确识别。首先利用具有全局搜索能力的QVSA优化T⁃S模糊推理模型的各种参数;然后利用主成分分析方法降低获取的地震属性维度;再利用优化的T⁃S模糊推理模型识别储层岩性。实验结果表明,利用反映储层特征的8个地震属性识别储层岩性时,所提方法的识别正确率达到92%,比普通BP网络方法高5.1%,同时查准率、查全率、F1分数等指标也较BP网络方法提升明显。